| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Guardant Health, Inc.$161.99
+9.64 (+6.33%)
F 14Pipeline Score Tools & Services · Commercial
Market Cap
15.77 B
EPS
-3.40
P/E Ratio
-
Value Trade
269.68 M
SEC Financials
Q1 2026Dilution Risk
Revenue
301.67 M
R&D Expenses
91.04 M
Operating CF
-65.62 M
Total Assets
1.92 B
Total Liabilities
2.10 B
Equity
-181.07 M
D/E Ratio
12,345
22.24 %
Week
29.69 %
1 Month
10.14 %
3 Month
19.25 %
6 Month
-3.01 %
5 Year
328.65 %
All Time
Cash Data
Cash Position
1.10 B
Monthly Burn
21.87 M
Runway
47.7 mo
Burn Trend
SEC Filing
May 7, 2026
Overview
Volume
4.58 M
52 Week Range
37.73 - 121.01
% held by Insiders
4.01 %
% held by Institutions
104.44 %
Enterprise Value
16.37 B
Total Shares
132.61 M
Short %
9.1 %
Float Shares
125.45 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Guardant Health, Inc.
208Total events
0Upcoming
68Tier-1 (high impact)
2019 – 2026Coverage
Event history 2
TBD
◆Quarterly UpdateCorporate
Subscribe to view catalyst details
TBD
▲Product LaunchShieldApprovedPost-Market
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
2025-01-25 | Guardant Reveal™ | Phase 2 data readout | Phase 2 | — | – | – | – |
2025-01-25 | Guardant Reveal™ | Phase 2 data readout | Phase 2 | — | – | – | – |
2025-01-25 | Guardant Reveal™ | Phase 2 data readout | Phase 2 | — | – | – | – |
Drug Pipeline Intelligence
F14
Pipeline Score -
Pipeline ValueValuation Signal
0
Drugs Scored—
rNPV / MCap Top 10%
Mid Cap (rank 833 of 924)
Percentile RankGuardant Health, Inc. Common Stock has significant pipeline risk (14/100).
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Shield blood test | colorectal cancer | — | 2023-05-09 | sensitivity: 83%; specificity: 90%; stage I III sensitivity: 73%; localized case sensitivity: 70% Read More | Guardant Health presents additional information from ECLIPSE study at 2023 Digestive Disease Week on the performance of Shield blood test Shield blood test achieved overall 83% sensitivity and 90% specificity and demonst Read More | |
Shield blood test | colorectal cancer | — | 2023-05-09 | sensitivity: 83%; specificity: 90%; stage I III sensitivity: 73%; localized case sensitivity: 70% Read More | Guardant Health presents additional information from ECLIPSE study at 2023 Digestive Disease Week on the performance of Shield blood test Shield blood test achieved overall 83% sensitivity and 90% specificity and demonst Read More | |
Shield blood test | colorectal cancer | — | 2023-05-09 | sensitivity: 83%; specificity: 90%; stage I III sensitivity: 73%; localized case sensitivity: 70% Read More | Guardant Health presents additional information from ECLIPSE study at 2023 Digestive Disease Week on the performance of Shield blood test Shield blood test achieved overall 83% sensitivity and 90% specificity and demonst Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in GH
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
GH Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-08-21 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-08-21 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-08-21 | 0.00 | 0 | - | - | - | - | - | - | ||||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
GH▲ +6.3%on this news
Guardant Health Reports Second Quarter 2026 Financial Results and Increases 2026 Revenue Guidance
Guardant Health, Inc. reported its financial results for the second quarter of 2026, showing a significant increase in total revenue of 44% year-over-year. The oncology segment contributed $219.1 million, marking a 38% rise. Additionally, the company performed approximately 104,000 oncology tests, a 63% increase from the prior year.
Read more →GHActor and Cancer Advocate Patrick Dempsey Stars in Emotional Tribute Video From Guardant Health Memorializing Those Who Have Lost Their Lives to Colorectal Cancer
Guardant Health has launched a tribute video featuring Patrick Dempsey to honor over 55,000 Americans who will die from colorectal cancer this year. The video emphasizes the critical need for timely colorectal cancer screenings, as many victims are not up to date with their screenings. This initiative aims to raise awareness and encourage preventive measures.
Read more →GHGuardant Health to Report Second Quarter 2026 Financial Results on July 30, 2026
Guardant Health, a precision oncology company, will report its second quarter 2026 financial results on July 30, 2026. The announcement includes a conference call scheduled for 1:30 p.m. PT, which will be webcasted for investor access. This event highlights the company's commitment to transparency and investor relations.
Read more →GHUnitedHealth Group Now Covers Guardant Health’s Shield Blood Test for Colorectal Cancer Screening
UnitedHealth Group has announced that it will now cover Guardant Health's Shield Blood Test for colorectal cancer screening. This test provides a non-invasive method for detecting colorectal cancer, which could lead to earlier diagnosis and treatment. The coverage expansion is expected to enhance access to this innovative screening option for patients.
Read more →GHGuardant Health Announces FDA Approval of Guardant360 CDx as Companion Diagnostic for Boehringer Ingelheim’s HERNEXEOS®
Guardant Health has received FDA approval for its Guardant360 CDx as a companion diagnostic for Boehringer Ingelheim's HERNEXEOS®. This approval marks a significant advancement in personalized medicine, allowing for better-targeted therapies. The collaboration aims to improve patient outcomes by providing more precise treatment options.
Read more →GHGuardant Health and Collaborators to Present 38 Abstracts Highlighting Breadth and Expanded Clinical Utility of Guardant Liquid Biopsy Tests Powered by InfinityAI at 2026 ASCO Annual Meeting
Guardant Health, alongside collaborators, will present 38 abstracts at the 2026 ASCO Annual Meeting. These abstracts will showcase the breadth and expanded clinical utility of Guardant's liquid biopsy tests, enhanced by their InfinityAI technology. This presentation aims to highlight advancements in cancer diagnostics and treatment monitoring.
Read more →GH▲ +6.4%on this newsshared move
American Cancer Society Recommends Guardant Health’s Shield Blood Test in Updated Colorectal Cancer Screening Guidelines
The American Cancer Society has updated its colorectal cancer screening guidelines to include Guardant Health's Shield blood test. This endorsement is expected to enhance early detection efforts for colorectal cancer. The inclusion of the Shield test reflects a growing recognition of non-invasive screening methods in cancer care.
Read more →GH▲ +17.1%on this news
FDA Approves New Guardant360 Liquid CDx, the Largest FDA-Approved Liquid Biopsy Panel with a 100x Expanded Footprint
The FDA has approved the new Guardant360 Liquid CDx, marking it as the largest liquid biopsy panel available. This approval expands its footprint by 100 times, significantly enhancing diagnostic capabilities in oncology. The approval reflects the FDA's confidence in the technology's effectiveness in providing critical insights for patient care.
Read more →GHGuardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Guardant Health has announced inducement grants under Nasdaq Listing Rule 5635(c)(4). The details of the grants and their implications for the company were not provided in the article. This announcement is part of the company's compliance with Nasdaq regulations.
Read more →GHDocument Guardant Health Reports First Quarter 2026 Financial Results and Increases 2026 Revenue Guidance First quarter 2026 revenue growth of 48% driven by strong performance in Oncology and Screening Raises 2026 revenu
Guardant Health reported a remarkable 48% increase in revenue for Q1 2026, reaching $301.7 million, driven by strong performances in oncology and screening sectors. The company adjusted its revenue guidance for the full year 2026 to between $1.30 and $1.32 billion, reflecting anticipated growth in oncology and screening contributions. Despite these positive developments, Guardant faced increasing operating expenses and a net loss of $112.1 million, raising concerns about profitability. The company has also expanded its capabilities and partnerships in precision oncology, enhancing its competitive position in the market.
Read more →GHGuardant Health Reports First Quarter 2026 Financial Results and Increases 2026 Revenue Guidance
Guardant Health has reported its financial results for the first quarter of 2026, alongside an increase in its revenue guidance for the year. The company aims to provide better forecasts based on its recent performance. Further details on the financial specifics were not disclosed in the article.
Read more →GHGuardant Health Receives FDA Approval for Guardant360® CDx as a Companion Diagnostic for Arvinas and Pfizer’s VEPPANU (vepdegestrant) for Patients with ER+/HER2- Advanced Breast Cancer with ESR1 Mutations
Guardant Health has received FDA approval for its Guardant360® CDx as a companion diagnostic for Arvinas and Pfizer’s VEPPANU (vepdegestrant). This approval specifically targets patients with ER+/HER2- advanced breast cancer who have ESR1 mutations. The collaboration aims to enhance treatment options for this patient population.
Read more →GHGuardant Health Announces Multi-Year Strategic Collaboration with Nuvalent to Develop Companion Diagnostics and Support Potential Commercialization of Targeted Cancer Therapies Using the Guardant Infinity™ Platform
Guardant Health has entered a multi-year strategic collaboration with Nuvalent to advance the development of companion diagnostics and support the commercialization of targeted cancer therapies. This partnership aims to leverage the Guardant Infinity™ platform, which offers both tissue and liquid biopsy options, enhancing precision in oncology treatments.
Read more →GHGuardant Health to Participate in Upcoming Investor Conferences
Guardant Health, Inc. has announced its participation in several upcoming investor conferences, including the BofA Securities 2026 Healthcare Conference and the William Blair 46th Annual Growth Stock Conference. These events will provide the company with a platform to discuss its advancements in precision oncology and engage with investors. Live and archived webcasts will be available on their website.
Read more →GH▲ +5.4%on this news
Guardant Health to Report First Quarter 2026 Financial Results on May 7, 2026
Guardant Health, a precision oncology company, will report its financial results for Q1 2026 on May 7, 2026. The announcement includes a conference call scheduled for 1:30 p.m. PT, which will be available via webcast. The company emphasizes its commitment to enhancing cancer care through innovative testing and analytics.
Read more →GHDocument Guardant Health Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Outlook Fourth quarter 2025 revenue growth of 39% broadly driven by strong performance across Oncology and Screening
Guardant Health reported a strong financial performance for the fourth quarter and full year of 2025, with a 39% increase in revenue compared to the same period in 2024. The company's total revenue for 2025 reached $982 million, up 33%. Highlights included strong growth in oncology and screening services, with an anticipated revenue boost of 27% to 30% in 2026. However, the company reported a net loss of $128.5 million for Q4 2025 and saw a rise in operating expenses.
Read more →GHGuardant Health Launches Community Colorectal Cancer Screening Grant Program in Recognition of CRC Awareness Month, Applications Now Open Ahead of Colorectal Cancer (CRC) Awareness Month in March, Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced...
Guardant Health has launched a Community Colorectal Cancer Screening Grant Program to support community-led screening efforts in March, coinciding with Colorectal Cancer Awareness Month. The program will provide up to 100 Shield tests at no cost to selected organizations, aiming to increase screening participation and awareness. This initiative highlights the company's commitment to improving access to colorectal cancer screening, particularly in underserved communities.
Read more →GH▼ -6.1%on this news
Guardant Health to Participate in Upcoming Investor Conferences - February 3, 2026
Guardant Health, a precision oncology company, has announced its participation in upcoming investor conferences. The company aims to enhance investor engagement and showcase its advancements in cancer therapies. Interested parties can access live and archived webcasts of the sessions through the company's website. Guardant Health continues to focus on improving cancer outcomes through innovative testing methods.
Read more →GHGuardant Health to Report Fourth Quarter and Full Year 2025 Financial Results on February 19, 2026
Guardant Health, Inc. has announced that it will report its financial results for the fourth quarter and full year 2025 on February 19, 2026. The report will be released after market close, followed by a conference call at 1:30 p.m. Pacific Time. The event will be available for live streaming and later replay on the company’s website.
Read more →GHGuardant Health Receives FDA Approval for Guardant360® CDx as Companion Diagnostic for BRAFTOVI® (encorafenib) Combination in Patients with BRAF V600E-Mutant Metastatic Colorectal Cancer
Guardant Health has received FDA approval for Guardant360® CDx as a companion diagnostic for identifying patients with BRAF V600E-mutant metastatic colorectal cancer (mCRC) who may benefit from encorafenib treatment. This approval is based on positive results from the Phase 3 BREAKWATER trial, which showed improved survival rates with encorafenib-based therapies. The test allows for non-invasive genomic testing, facilitating timely treatment decisions.
Read more →GHGuardant Health Announces Multi-Year Strategic Collaboration Agreement with Merck to Develop Companion Diagnostics and Commercialize New Cancer Therapies Using Guardant Infinity Smart Platform
Guardant Health has entered a multi-year strategic collaboration with Merck to develop companion diagnostics using the Guardant Infinity Smart platform. This partnership aims to enhance the development and commercialization of Merck's oncology portfolio, emphasizing the importance of biomarkers in therapy selection. The collaboration is expected to accelerate the delivery of innovative cancer therapies.
Read more →GHGuardant Health Announces Preliminary Fourth Quarter and Full Year 2025 Results Fourth quarter revenue growth of 39% driven by strong Oncology and Screening volume
Guardant Health has announced preliminary unaudited financial results showing a 39% revenue growth for Q4 2025, totaling approximately $280 million, primarily driven by strong performance in their oncology and screening divisions. The company reported significant increases in test volumes, with 79,000 oncology tests and 38,000 Shield screening tests conducted in this period. While revenue growth signals a breakout year, there are concerns as the company posted negative free cash flow for both the fourth quarter and full year. Financial results remain non-final, and the company warns of risks related to forward-looking statements.
Read more →GHGuardant Health Announces Pricing of Upsized Public Offering of Common Stock
Guardant Health has announced the pricing of an upsized public offering of 3,333,333 shares of common stock at $90 per share, increasing the offering from a total valuation of $250 million. The company expects net proceeds of about $284.4 million, which may be used for corporate purposes including potential repurchases of convertible notes. The offering, along with a concurrent convertible notes offering, is set to close on November 7, 2025. This move reflects growing investor interest and market confidence in Guardant Health's business model.
Read more →GHDocument Guardant Health Reports Third Quarter 2025 Financial Results and Increases 2025 Revenue Guidance Revenue growth of 39% broadly driven by strong performance across Oncology, Screening, and Biopharma Data Raises 2
Guardant Health reported a strong performance for the third quarter of 2025, with revenues reaching $265.2 million, representing a 39% increase from the previous year. The revenue growth was primarily driven by significant demand in Oncology testing and the launch of the Shield screening tests, now expanded to include multi-cancer detection. The company also raised its revenue guidance for the year to between $965 million and $970 million, reflecting positive trends in its business segments. However, Guardant reported a net loss of $92.7 million, highlighting ongoing operational challenges amid its growth trajectory.
Read more →GHAlex M. Azar II Joins Guardant Health Board of Directors
Guardant Health, a precision oncology company, announced the appointment of Alex M. Azar II to its board of directors. Azar, who previously served as the Secretary of the U.S. Department of Health and Human Services, brings valuable experience from both the public and private sectors. His expertise is expected to help advance Guardant's mission of improving cancer care through innovative technologies. The company is recognized for pioneering liquid biopsy technology, which enhances the early detection and management of cancer.
Read more →GHDocument Guardant Health Reports Second Quarter 2025 Financial Results and Increases 2025 Revenue Guidance Revenue growth of 31% broadly driven by strong performance across Oncology, Screening, and Biopharma Data Raises
Guardant Health reported its financial results for the second quarter of 2025, showing a revenue growth of 31% from the previous year, amounting to $232.1 million. The company increased its full-year revenue guidance to between $915 million and $925 million, reflecting strong contributions from its oncology, screening, and biopharma sectors. Despite the positive trends in revenue, the company reported a net loss of $99.9 million, although this was an improvement compared to the same quarter last year. Additionally, the firm continues to innovate in its product offerings, having launched 11 new Smart Liquid Biopsy applications and received FDA recognition for its Shield test.
Read more →GHDocument Guardant Health Reports First Quarter 2025 Financial Results and Increases 2025 Revenue Guidance Revenue growth of 21% broadly driven by strong performance across oncology, screening, and biopharma data Raises 2
Guardant Health reported a robust 21% revenue growth in Q1 2025, reaching $203.5 million, and raised its annual revenue guidance to $880-$890 million. The company saw significant increases across its oncology and biopharma data segments, driven by stronger test volumes and product enhancements. Despite these positive trends, Guardant Health incurred a net loss of $95.2 million, although this represented an improvement from the previous year. The business plans to continue investments in its screening commercial infrastructure, expecting to reach cash flow breakeven by the end of 2025.
Read more →GHDocument Guardant Health Reports Fourth Quarter and Full Year 2024 Financial Results and Provides 2025 Outlook Full year 2024 total revenue growth of 31% driven by strong clinical oncology volume growth, Guardant360 ASP
Guardant Health reported impressive financial results for the fourth quarter and the full year of 2024, boasting a 31% increase in total revenue driven by strong growth in clinical oncology and biopharma tests. The company anticipates continued growth into 2025, projecting total revenue between $850 million and $860 million. Significant milestones include receiving Medicare reimbursement for Guardant Reveal and being selected for multiple studies and collaboration projects, enhancing its position in precision oncology. Despite a noteworthy net loss of $111 million in Q4, the overall fiscal health showed improvement relative to the previous year.
Read more →GHGuardant Health Announces Debt Exchange Transactions
Guardant Health has announced a series of debt exchange transactions involving the replacement of $659.3 million in older Convertible Senior Notes due 2027 with $600 million in new Convertible Senior Notes due 2031. This process aims to enhance financial flexibility and improve the company’s balance sheet. Additionally, the company plans to repurchase approximately $80 million worth of its shares as part of this transaction. The completion of this exchange is expected around February 14, 2025, pending customary conditions.
Read more →GHGuardant Health Announces Preliminary Fourth Quarter and Full Year 2024 Results Full year revenue growth of 31% driven by strong clinical and biopharma volume and Guardant360 ASP tailwinds
Guardant Health has announced preliminary financial results for Q4 and the full year of 2024, reporting a revenue growth of 31%, driven by high volume in clinical and biopharma segments. The company is optimistic about its future growth potential, particularly following the successful launch of Shield. However, the results are unaudited and subject to change, as indicated by the negative free cash flow of approximately $84 million for the fourth quarter and $275 million for the full year.
Read more →GH▲ +7.5%on this news· ran to +25% by day 3
Document Guardant Health Reports Third Quarter 2024 Financial Results and Increases 2024 Revenue Guidance Revenue growth of 34% driven by strong clinical and biopharma volume and Guardant360 ASP tailwinds Shield received
Guardant Health reported robust financial results for Q3 2024, with revenues increasing by 34% to $191.5 million driven by strong clinical and biopharma test volumes. The company raised its annual revenue guidance to a range of $720 to $725 million, marking a growth forecast of 28% to 29%. Despite the positive revenue growth and favorable Medicare pricing for its newly launched Shield IVD product, Guardant Health continues to face significant net losses and increased operational costs, indicating areas of concern that may affect future financial stability.
Read more →GHRoberto A. Mignone Joins Guardant Health Board of Directors PALO ALTO, Calif.-- (
Guardant Health has appointed Roberto A. Mignone to its board of directors, effective immediately. Mignone, Founder and Managing Partner of Bridger Management LLC, brings extensive experience in healthcare and business strategy. His appointment coincides with the recent FDA approval of Guardant's colorectal cancer screening product, Shield. The company anticipates that Mignone's perspective will enhance their product offerings and positively impact patient care.
Read more →GH▲ +5.6%on this news
Document Guardant Health Reports Second Quarter 2024 Financial Results and Increases 2024 Revenue Guidance Revenue growth of 29% driven by strong clinical and biopharma volume and Guardant360 ASP tailwinds Shield approve
Guardant Health reported robust financial results for the second quarter of 2024, with revenue growth of 29% year-over-year, totaling $177.2 million. The company received FDA approval for its Shield blood test for colorectal cancer, which is now available for over 45 million Medicare beneficiaries. Additionally, Guardant forecasted improved 2024 revenue guidance, estimating between $690 million to $700 million, reflecting a growth of 22% to 24%. Despite these achievements, Guardant Health experienced an increase in net loss, rising to $102.6 million, which raises concerns about ongoing operating expenses.
Read more →GH▲ +6.9%on this news
Guardant Health s Shield TM blood test approved by FDA as a primary screening option, clearing path for Medicare reimbursement and a new era of colorectal cancer screening Shield is first blood test approved
Guardant Health's Shield blood test has received FDA approval as the first primary screening option for colorectal cancer in individuals aged 45 and older at average risk. This approval is expected to enhance screening rates and early detection of colorectal cancer, a critical factor in treatment success. The test has demonstrated high sensitivity and specificity in clinical trials, providing a non-invasive method for cancer screening. The decision also paves the way for Medicare reimbursement, expanding patient access to this innovative screening tool.
Read more →GHDr. Manuel Hidalgo Medina Joins Guardant Health Board of Directors PALO ALTO, Calif. (
Guardant Health, Inc. has appointed Dr. Manuel Hidalgo Medina to its board of directors, effective immediately. Dr. Hidalgo, who is the Chief of the Division of Hematology and Medical Oncology at Weill Cornell Medicine, brings considerable experience in clinical and translational oncology research. His background includes significant roles in prestigious cancer centers and a commitment to advancing patient care through innovative cancer diagnostics. The company welcomes Dr. Hidalgo's expertise as it continues to focus on improving outcomes for cancer patients.
Read more →GH▲ +13.4%on this news
FDA Advisory Committee Panel Strongly Recommends Approval of Shield Blood Test for Colorectal Cancer Screening as a Primary Non-Invasive Screening Option
The FDA Advisory Committee has strongly recommended the approval of Guardant Health's Shield blood test for colorectal cancer screening in average-risk adults over 45. This recommendation underscores the test's safety and efficacy, emphasizing its ability to potentially enhance colorectal cancer screening rates. With colorectal cancer being a leading cause of cancer deaths in the U.S., the approval of Shield could provide a crucial non-invasive option for early detection. The final decision by the FDA is expected later this year.
Read more →GHDocument Guardant Health Reports First Quarter 2024 Financial Results and Increases 2024 Revenue Guidance Revenue growth of 31% driven by strong clinical and biopharma volume and Guardant360 ASP tailwinds
Guardant Health reported strong financial results for Q1 2024, with a revenue increase of 31% year-over-year, reaching $168.5 million. The company saw significant growth in testing volumes, particularly for biopharmaceutical customers, and improved free cash flow guidance. However, it still experienced a net loss of $115 million, albeit smaller compared to previous losses. Guardant Health also raised its revenue forecast for the year, reflecting a positive outlook for its operations.
Read more →GHDocument Guardant Health Reports Fourth Quarter and Full Year 2023 Financial Results and Provides 2024 Outlook Full year 2023 revenue growth of 25% driven by clinical volume growth of 39% Expects full year 2024 revenue t
Guardant Health reported a revenue increase of 25% for 2023, driven by a 39% growth in clinical testing volume. The company anticipates 2024 revenues between $655 million and $670 million, focusing on continued expansion in its precision oncology offerings. Despite a net loss of $479.4 million for the year, improvements in cash flow and clinical service volumes were noted. The upcoming launch of the Shield IVD test, pending FDA approval, is expected to boost their screening business significantly.
Read more →GHGuardant Health Announces Preliminary Fourth Quarter and Full Year 2023 Results Full year revenue growth of 25% driven by clinical volume growth of 39%
Guardant Health, Inc. has announced its preliminary fourth quarter and full year 2023 results, reporting a remarkable 25% revenue growth for the year, driven by a clinical volume increase of 39%. Despite strong revenue performance, the company faced substantial financial challenges, with negative cash flow of approximately $84 million in Q4 and $347 million for the full year. Anticipating further growth, the company expressed optimism about the upcoming launch of the Shield IVD test, pending FDA approval. However, all financial results are preliminary and may be adjusted upon final audit.
Read more →GH▲ +8.2%on this news
Guardant Health Announces $90.7 Million Registered Direct Offering with Baillie Gifford
Guardant Health has announced a registered direct offering of 3,387,446 shares at an offering price of $26.77 per share, generating gross proceeds of approximately $90.7 million. The offering was made in partnership with Baillie Gifford, reflecting strong investor backing for Guardant's precision oncology initiatives. The funds are intended for general corporate purposes, including working capital and operating expenses. This move is part of Guardant's strategy to enhance patient outcomes and expand its product portfolio.
Read more →GHGuardant Health Announces Tentative Date of FDA Advisory Panel Review of Shield Blood Test
Guardant Health, Inc. has announced that the FDA's Molecular and Clinical Genetics Panel is tentatively scheduled to review its Shield blood test for colorectal cancer on March 28, 2024. This review follows the submission of the final module of the premarket approval application, supported by data from the over 20,000-patient ECLIPSE study. The company aims to address the screening gap for colorectal cancer once FDA approval is received. The scheduled review aligns with Guardant's expectations for completing the PMA process and launching the Shield test.
Read more →GH▼ -6.8%on this news
Guardant Health to Appeal Federal District Court Verdict PALO ALTO, Calif. - (BUSINESS WIRE) - (
Guardant Health, Inc. has announced its intent to appeal a recent unfavorable verdict from the U.S. District Court for the District of Delaware regarding intellectual property claims by TwinStrand Biosciences and the University of Washington. Co-CEO Helmy Eltoukhy expressed strong disagreement with the decision, emphasizing the company's belief in the merits of its research and intellectual property. Guardant plans to file additional motions and pursue the case through the appeals court, highlighting its confidence in addressing the issues at hand.
Read more →GHDocument Guardant Health Reports Third Quarter 2023 Financial Results and Increases Revenue Guidance Q3 revenue increased 22% year over year driven by clinical volume growth of 35% Raises 2023 revenue guidance to $553 to
Guardant Health reported its financial results for Q3 2023, showing a revenue increase of 22% compared to the previous year, driven by strong clinical volume growth of 35%. The company raised its full-year revenue guidance, now expecting between $553 million and $556 million. Despite these gains, Guardant posted a net loss of $86.1 million and experienced a 37% decline in development services revenue. The company continues to expand its clinical offerings and has seen promising developments in its oncology testing products.
Read more →GHDocument Guardant Health Reports Second Quarter 2023 Financial Results and Increases Revenue Guidance Q2 revenue increased 26% year over year driven by clinical volume growth of 49% Raises 2023 revenue guidance to $545 t
Guardant Health, Inc. reported significant financial growth in its second quarter of 2023, with a 26% revenue increase to $137.2 million compared to the same quarter in 2022. The company's clinical volume saw a notable rise of 49%, prompting Guardant to raise its full-year revenue guidance to between $545 million and $550 million. Despite the positive revenue growth, Guardant reported a net loss of $72.8 million and high operating expenses, highlighting challenges in profitability. The company continues to focus on expanding its offerings in precision oncology and plans to launch new testing technologies in the near future.
Read more →GHGuardant resolves pending litigation with Illumina and enters into new agreement to advance long-term commercial partnership and cancer research
Guardant Health has resolved its pending litigation with Illumina, leading to a new three-year agreement that enhances their long-term commercial partnership. The agreement includes a request to dismiss the litigation with prejudice, allowing both companies to focus on collaborative efforts in cancer research. Additionally, they will share specimen samples and commit to a long-term purchase and supply agreement. This resolution reflects Guardant's commitment to leveraging its technologies for better cancer care globally.
Read more →GHGuardant Health presents additional information from ECLIPSE study at 2023 Digestive Disease Week on the performance of Shield blood test Shield blood test achieved overall 83% sensitivity and 90% specificity and demonst
Guardant Health presented additional findings from the ECLIPSE study at the Digestive Disease Week, highlighting the performance of its Shield blood test for colorectal cancer detection. The study, involving over 20,000 participants, demonstrated that the test achieved 83% sensitivity and 90% specificity, comparing favorably to existing non-invasive screening options. This technology aims to address the significant gap in colorectal cancer screening adherence, especially among minority groups. The results suggest that the Shield test could lead to earlier detection and better outcomes for patients.
Read more →GHDocument Guardant Health Reports First Quarter 2023 Financial Results Q1 revenue increased 34% year over year driven by clinical volume growth of 45% Raises 2023 revenue guidance to $535 to $545 million
Guardant Health reported strong first quarter 2023 financial results, with a 34% year-over-year revenue increase to $128.7 million, driven by significant clinical volume growth. The company raised its 2023 revenue guidance to between $535 million and $545 million, reflecting optimistic expectations for the year. Recent FDA approvals and expanded Medicare coverage are expected to further boost growth in their precision oncology offerings. However, the company also reported an increased net loss of $133.5 million and rising operating expenses, raising concerns about cost management.
Read more →GHGuardant Health Announces Additions to Leadership Team Ines Dahne-Steuber named as chief operating officer Darya Chudova promoted to chief technology officer
Guardant Health has expanded its leadership team by appointing Ines Dahne-Steuber as chief operating officer and promoting Darya Chudova to chief technology officer. Dahne-Steuber brings over 20 years of experience in healthcare operations, while Chudova has significantly contributed to Guardant's technology development for eight years. These changes are meant to enhance operational efficiency and support upcoming product launches as the company scales globally. Both leaders are viewed as instrumental in furthering the company's mission in precision oncology.
Read more →GH▲ +5.1%on this news
Musa Tariq joins Guardant Health board of directors
Guardant Health announced the appointment of Musa Tariq to its board of directors, effective March 6, 2023. Tariq, currently the chief marketing officer for GoFundMe, is recognized for his extensive marketing experience with notable companies. He expressed excitement to join at a crucial time for the company as it strives to enhance cancer care through innovative testing methods. His strategic insight is expected to be invaluable as Guardant Health continues to evolve in the oncology field.
Read more →GH▼ -6.5%on this newsshared move
Document Guardant Health Reports Fourth Quarter and Full Year 2022 Financial Results and Provides 2023 Outlook Q4 clinical and biopharma volumes up 41% and 24% year over year
Guardant Health reported its fourth quarter and full year 2022 financial results, showing a year-over-year revenue increase of 20% to $449.5 million. Notably, clinical and biopharma testing volumes rose substantially, with Q4 figures up 41% and 24%, respectively. The company announced FDA approval for its Guardant360 CDx test as a companion diagnostic for advanced breast cancer, indicating successful regulatory advancements. Despite these successes, Guardant experienced a significant net loss of $654.6 million for the year, raising concerns about rising operating costs.
Read more →GH▲ +7.1%on this news· ran to +18% by day 3
Document Guardant Health Announces Preliminary Fourth Quarter and Full Year 2022 Results Full year clinical and biopharma volumes up 42% and 40% year over year
Guardant Health, a precision oncology company, reported strong preliminary financial results for 2022, with a revenue increase of 20% and significant growth in clinical and biopharma test volumes. The company reported 124,800 clinical tests and 26,000 biopharma tests, marking increases of 42% and 40%, respectively. Co-CEOs Helmy Eltoukhy and AmirAli Talasaz expressed optimism for future growth and received positive feedback on their ECLIPSE trial Shield test. However, the preliminary nature of these results presents some uncertainty regarding the final financial reporting.
Read more →GHDocument Guardant Health announces positive results from pivotal ECLIPSE study evaluating a blood test for the detection of colorectal cancer The test demonstrated 83% sensitivity for the detection of colorectal cancer w
Guardant Health announces positive results from pivotal ECLIPSE study evaluating a blood test for the detection of colorectal cancer The test demonstrated 83% sensitivity for the detection of colorectal cancer with specificity of 90% Results pave the way for first potential FDA
Read more →GHDocument Guardant Health Reports Third Quarter 2022 Financial Results Q3 clinical and biopharma volumes up 42% and 40% year over year
Guardant Health Reports Third Quarter 2022 Financial Results Q3 clinical and biopharma volumes up 42% and 40% year over year PALO ALTO, Calif. November 3, 2022 - Guardant Health, Inc. (Nasdaq GH), a leading precision oncology company focused on helping conquer cancer globally t
Read more →GHDocument Guardant Health Reports Second Quarter 2022 Financial Results Q2 clinical and biopharma volumes up 40% and 65% year over year
Guardant Health Reports Second Quarter 2022 Financial Results Q2 clinical and biopharma volumes up 40% and 65% year over year PALO ALTO, Calif. August 4, 2022 - Guardant Health, Inc. (Nasdaq GH), a leading precision oncology company focused on helping conquer cancer globally th
Read more →GH▲ +8.9%on this news
Steve E. Krognes Joins Guardant Health Board of Directors
Steve E. Krognes Joins Guardant Health Board of Directors PALO ALTO, Calif. July 7, 2022 Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the appointment of Steve E. Krognes to its board of directors. Mr. Krognes is a professional indepe
Read more →GHGuardant Health Completes Purchase of Guardant Health AMEA Joint Venture
Guardant Health Completes Purchase of Guardant Health AMEA Joint Venture PALO ALTO, Calif. June 13, 2022 Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it has purchased the remaining shares of Guardant Health AMEA, Inc. held by SoftBan
Read more →GH▼ -9.8%on this news· ran to -44% by day 3
Document Guardant Health Reports First Quarter 2022 Financial Results Q1 clinical and biopharma volumes up 47% and 45% year over year
Guardant Health Reports First Quarter 2022 Financial Results Q1 clinical and biopharma volumes up 47% and 45% year over year PALO ALTO, Calif. May 5, 2022 - Guardant Health, Inc. (Nasdaq GH), a leading precision oncology company focused on helping conquer cancer globally throug
Read more →GHDocument Guardant Health Reports Fourth Quarter 2021 Financial Results and Provides 2022 Outlook Q4 clinical and biopharma volumes up 48% and 36% year over year
Guardant Health Reports Fourth Quarter 2021 Financial Results and Provides 2022 Outlook Q4 clinical and biopharma volumes up 48% and 36% year over year REDWOOD CITY, Calif. February 23, 2022 - Guardant Health, Inc. (Nasdaq GH), a leading precision oncology company focused on he
Read more →GHGuardant Health and Foundation Medicine Reach Settlement in Digital Sequencing Technology Litigation
Guardant Health and Foundation Medicine Reach Settlement in Digital Sequencing Technology Litigation REDWOOD CITY, Calif. January 7, 2022 Guardant Health, Inc. (Nasdaq: GH) today announced that it has reached an agreement to settle all pending litigation concerning the company
Read more →GHDocument Guardant Health Reports Third Quarter 2021 Financial Results Achieved record revenue of $94.8 million Growth of 35% and 58% year over year in clinical and biopharma volumes, respectively
Guardant Health Reports Third Quarter 2021 Financial Results Achieved record revenue of $94.8 million Growth of 35% and 58% year over year in clinical and biopharma volumes, respectively REDWOOD CITY, Calif. November 4, 2021 - Guardant Health, Inc. (Nasdaq GH), a leading preci
Read more →GHGuardant Health Appoints Myrtle Potter to its Board of Directors
Health Appoints Myrtle Potter to its Board of Directors REDWOOD CITY, Calif. October 20, 2021 (BUSINESS WIRE) Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, has appointed Myrtle Potter to serve on its Board of Directors. pleased to welcome Myrtle Pot
Read more →GHGuardant Health Announces New Leadership Structure Aligned with Strategic Growth Objectives and Expands Board of Directors
Guardant Health Announces New Leadership Structure Aligned with Strategic Growth Objectives and Expands Board of Directors REDWOOD CITY, Calif. August 5, 2021 (BUSINESS WIRE) Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, has announced a new leadershi
Read more →GHDocument Guardant Health Reports Second Quarter 2021 Financial Results Achieved revenue of $92.1 million, driven by 52% year over year growth in clinical volume
Guardant Health Reports Second Quarter 2021 Financial Results Achieved revenue of $92.1 million, driven by 52% year over year growth in clinical volume REDWOOD CITY, Calif. August 5, 2021 - Guardant Health, Inc. (Nasdaq GH), a leading precision oncology company focused on helpi
Read more →GHDocument Guardant Health Reports First Quarter 2021 Financial Results Achieved revenue of $78.7 million, driven by approximately 18,400 clinical tests
Guardant Health Reports First Quarter 2021 Financial Results Achieved revenue of $78.7 million, driven by approximately 18,400 clinical tests REDWOOD CITY, Calif. May 6, 2021 - Guardant Health, Inc. (Nasdaq GH), a leading precision oncology company focused on helping conquer ca
Read more →GHDocument Guardant Health Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Revenue Outlook for Full Year 2021 2020 Revenue Increased 34% Over Prior Year Period
Guardant Health Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Revenue Outlook for Full Year 2021 2020 Revenue Increased 34% Over Prior Year Period REDWOOD CITY, Calif. February 24, 2021 - Guardant Health, Inc. (Nasdaq GH), a leading precision oncology
Read more →GHJ.P. Morgan Healthcare Conference
99.1 J.P. Morgan Healthcare Conference January 11, 2021 Safe Harbor Certain statements in this presentation and the accompanying oral commentary are forward-looking statements within the meaning of federal securities laws. These statements relate to future events or Guardant He
Read more →GHGuardant Health Names Michael Bell as New Chief Financial Officer
Guardant Health Names Michael Bell as New Chief Financial Officer REDWOOD CITY, Calif. December 11, 2020 (BUSINESS WIRE) Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, has named Michael Bell as the company s new Chief Financial Officer (CFO) effective
Read more →GHGuardant Health, Inc. Announces Proposed Convertible Senior Notes Offering Redwood City, California (BUSINESS WIRE)
Guardant Health, Inc. Announces Proposed Convertible Senior Notes Offering Redwood City, California (BUSINESS WIRE) Nov. 16, 2020 Guardant Health, Inc. (Nasdaq: GH) today announced its intention to offer, subject to market and other conditions, $1,000,000,000 aggregate principa
Read more →GHDocument Guardant Health Reports Third Quarter 2020 Financial Results Q3 2020 Revenue Increase of 23% Over Prior Year Period
Guardant Health Reports Third Quarter 2020 Financial Results Q3 2020 Revenue Increase of 23% Over Prior Year Period REDWOOD CITY, Calif. November 5, 2020 - Guardant Health, Inc. (Nasdaq GH), a leading precision oncology company focused on helping conquer cancer globally through
Read more →GHDocument Guardant Health Reports Second Quarter 2020 Financial Results Q2 2020 Revenue Increase of 23% Over Prior Year Period
Guardant Health Reports Second Quarter 2020 Financial Results Q2 2020 Revenue Increase of 23% Over Prior Year Period REDWOOD CITY, Calif. August 6, 2020 - Guardant Health, Inc. (Nasdaq GH), a leading precision oncology company focused on helping conquer cancer globally through
Read more →GHGuardant Health Reports First Quarter 2020 Financial Results
Guardant Health Reports First Quarter 2020 Financial Results Q1 2020 Revenue Increase of 84% Over Prior Year Period REDWOOD CITY, Calif. May 7, 2020 - Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company focused on helping conquer cancer globally through use
Read more →GHGuardant Health Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Full Year 2020 Outlook
Guardant Health Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Full Year 2020 Outlook Full Year 2019 Revenue Increase of 137% Over 2018 REDWOOD CITY, Calif. February 24, 2020 - Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company fo
Read more →GHGuardant Health Reports Third Quarter 2019 Financial Results and Raises 2019 Revenue Guidance
Guardant Health Reports Third Quarter 2019 Financial Results and Raises 2019 Revenue Guidance Q3 2019 revenue increase of 181% over prior year period REDWOOD CITY, Calif. November 7, 2019 - Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company focused on help
Read more →Competitive Position
How GH ranks across every disease it competes inCompetitive Position is a premium feature
See how GH ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial